EditorialPublished 2012
Use Circulating microRNAs as Biomarkers of Drug-Induced Liver Injury
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Drug-Induced Liver Injury (DILI) is an adverse event that frequently leads to cessation of drug testing in clinical trials, restrictions on drug use, and drug withdrawals. Among the preclinical candidate compounds that are discontinued for organ toxicity, it is estimated that up to half are terminated due to hepatotoxicity. Existing biomarkers of liver injury (e.g., serum alanine aminotransferase [ALT] and bilirubin) provide reasonable indicators of damage; however, none of them has sufficient specificity and/or they are increased only after significant damage has occurred. New reliable biomarkers of DILI are urgently required for both clinical and preclinical pharmaceutical evaluation. Open access helps authors, who discover new DILI biomarkers, to maximize the impact of their research articles.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Xi Yang”